The first step to filing an Actos lawsuit is making sure you've been damaged. This can be emotionally or physically.
If you've been using the drug: Actos, even for a short while, and you've noticed something different, something uncomfortable or something strange, it would be wise to visit a doctor immediately. This will help you, also, in producing documentation when and if you file a lawsuit.
The drug Actos has had a growing number of complaints. Some of these complaints have resulted in fatalities. If you've been damaged or experienced anything negative as a result of using this drug, seek a competent lawyer to receive compensation.
You can seek the best legal advice and representation at no cost to you by clicking here.
Saturday, July 14, 2012
Friday, July 6, 2012
Information About Actos And Filing An Actose Lawsuit
Here are some videos about Actos and filing an Actose lawsuit.
Seen enough? Consult a lawyer easily and for free by clicking here.
Seen enough? Consult a lawyer easily and for free by clicking here.
Thursday, July 5, 2012
Actos Litigation Streamlined To Aid Victims
A recent order issued by a judicial panel will likely streamline the filing process for those who were injured by the diabetes drug Actos. Use of the medication - which is designed to treat type 2 diabetes - for more than one year allegedly increases the risk of heart failure and bladder cancer, along with other potentially severe side effects.
You can file an Actos lawsuit very easily by clicking here.
Cases against the manufacturer of Actos, Takeda Pharmaceuticals U.S.A., are being filed throughout the country. In an attempt to expedite relief for victims of the medication, the cases were consolidated in 2011. The lawsuits are now part of the multidistrict litigation overseen by U.S. District Judge Rebecca Doherty.
Details of Decision and Impact on Actos Victims
The Honorable Judge Doherty recently signed a Direct Filing and Service of Process Order. This Order is designed to simplify the litigation process for those injured by the medication by "eliminate[ing] delays associated with transfer" of cases.
The process will likely hasten resolution for victims, since cases can now be filed directly and no longer need to be filed first in a local court, and then subsequently await transfer to multidistrict litigation - removing one procedural hurdle for Actos victims.
Dangers Associated With Actos Use
Both Germany and France have pulled Actos from their shelves, citing concerns of increased health risks associated with prolonged use of the medication. Five days later, the Food and Drug Administration (FDA) released a warning citing similar concerns.
In fact, a study by the FDA found that those who took the medication for more than one year faced a 40 percent increased likelihood of developing bladder cancer when compared to those who have never taken the drug.
Additional allegations of macular edema and blindness are also receiving attention. If you or a loved one experienced one of these or another injury associated with use of Actos, remedies may be available.
Start the process of filing an Actos lawsuit by clicking here.
You can file an Actos lawsuit very easily by clicking here.
Cases against the manufacturer of Actos, Takeda Pharmaceuticals U.S.A., are being filed throughout the country. In an attempt to expedite relief for victims of the medication, the cases were consolidated in 2011. The lawsuits are now part of the multidistrict litigation overseen by U.S. District Judge Rebecca Doherty.
Details of Decision and Impact on Actos Victims
The Honorable Judge Doherty recently signed a Direct Filing and Service of Process Order. This Order is designed to simplify the litigation process for those injured by the medication by "eliminate[ing] delays associated with transfer" of cases.
The process will likely hasten resolution for victims, since cases can now be filed directly and no longer need to be filed first in a local court, and then subsequently await transfer to multidistrict litigation - removing one procedural hurdle for Actos victims.
Dangers Associated With Actos Use
Both Germany and France have pulled Actos from their shelves, citing concerns of increased health risks associated with prolonged use of the medication. Five days later, the Food and Drug Administration (FDA) released a warning citing similar concerns.
In fact, a study by the FDA found that those who took the medication for more than one year faced a 40 percent increased likelihood of developing bladder cancer when compared to those who have never taken the drug.
Additional allegations of macular edema and blindness are also receiving attention. If you or a loved one experienced one of these or another injury associated with use of Actos, remedies may be available.
Start the process of filing an Actos lawsuit by clicking here.
Yet Another Actos Bladder Cancer Lawsuit
Lafayette, LA: While Actos has recently come under the microscope for Actos macular edema, cases alleging the popular Type 2 diabetes drug triggered the onset of bladder cancer continue to roll in. One of the latest is that of a Virginia plaintiff who filed an Actos bladder cancer lawsuit last month in the US District Court for the Western District of Louisiana.
The plaintiff in Case No. 6:12-cv-1704 relied upon Actos to treat his diabetes from 2006 through 2011. In his Actos bladder cancer lawsuit, which is included in the Actos multidistrict litigation MDL No. 6:11-md-2299, the plaintiff alleges the defendant, Takeda Pharmaceuticals, possessed knowledge that long-term use of Actos could expose patients to an increased risk for bladder cancer, but failed to adequately notify consumers as to the risk.
It should be noted that various reports put Actos sales at $4.8 billion for 2011.
Seeing Actos and bladder cancer in the headlines appears to be an increasing phenomenon, although it wasn't always so. In fact, the Takeda drug was under the radar until competitor Avandia started grabbing headlines over reports of heart problems. Doctors switched their patients away from Avandia to Actos for management of Type 2 diabetes, and suddenly Actos was hot.
That heat has since cooled amidst reports of bladder cancer, but other Actos side effects including Actos heart failure (thought not to be as serious as that associated with Avandia) and Actos macular edema.
The latter is characterized by a build-up of fluid behind the eyes stemming from the leakage of fluid into the center of the macula, which contributes to sharpness of vision when peering straight on. Fluid build-up results in blurred vision, or macular edema.
Researchers conducting a study into Actos and edema (Avandia was also studied) noted that up to 20 percent of patients suffering from diabetes present with symptoms of macular edema. However, after studying data from more than 100,000 Type 2 diabetes patients from the database of the British Health Improvement Network, researchers found that 1.3 percent of patients taking thiazolidinediones, a class of drugs to which Actos belongs, developed macular edema compared with 0.2 percent of those not taking thiazolidinediones.
While the absolute risk for Actos macular edema remained small, "patients who received a thiazolidinedione were at two to three-fold increased risk of developing macular edema," said lead researcher Iskandar Idris, an associate professor in diabetes medicine at the University of Nottingham, in comments published last month in Consumer Health News (6/11/12). The study itself was published June 11 online in the Archives of Internal Medicine.
Beyond Actos edema, remains the alleged association between Actos and bladder cancer. Among the various reports damning Actos for its association with the onset of bladder cancer is a 10-year study (ongoing) undertaken by Kaiser Permanente, which found patients taking Actos for one year were 40 percent more likely to develop Actos bladder cancer compared with those who had never taken Actos. The Kaiser agency also noted the risk for bladder cancer increased with duration and dosage.
The plaintiff in the Actos lawsuit noted above had taken Actos for about five years.
The plaintiff in Case No. 6:12-cv-1704 relied upon Actos to treat his diabetes from 2006 through 2011. In his Actos bladder cancer lawsuit, which is included in the Actos multidistrict litigation MDL No. 6:11-md-2299, the plaintiff alleges the defendant, Takeda Pharmaceuticals, possessed knowledge that long-term use of Actos could expose patients to an increased risk for bladder cancer, but failed to adequately notify consumers as to the risk.It should be noted that various reports put Actos sales at $4.8 billion for 2011.
Seeing Actos and bladder cancer in the headlines appears to be an increasing phenomenon, although it wasn't always so. In fact, the Takeda drug was under the radar until competitor Avandia started grabbing headlines over reports of heart problems. Doctors switched their patients away from Avandia to Actos for management of Type 2 diabetes, and suddenly Actos was hot.
That heat has since cooled amidst reports of bladder cancer, but other Actos side effects including Actos heart failure (thought not to be as serious as that associated with Avandia) and Actos macular edema.
The latter is characterized by a build-up of fluid behind the eyes stemming from the leakage of fluid into the center of the macula, which contributes to sharpness of vision when peering straight on. Fluid build-up results in blurred vision, or macular edema.
Researchers conducting a study into Actos and edema (Avandia was also studied) noted that up to 20 percent of patients suffering from diabetes present with symptoms of macular edema. However, after studying data from more than 100,000 Type 2 diabetes patients from the database of the British Health Improvement Network, researchers found that 1.3 percent of patients taking thiazolidinediones, a class of drugs to which Actos belongs, developed macular edema compared with 0.2 percent of those not taking thiazolidinediones.
While the absolute risk for Actos macular edema remained small, "patients who received a thiazolidinedione were at two to three-fold increased risk of developing macular edema," said lead researcher Iskandar Idris, an associate professor in diabetes medicine at the University of Nottingham, in comments published last month in Consumer Health News (6/11/12). The study itself was published June 11 online in the Archives of Internal Medicine.
Beyond Actos edema, remains the alleged association between Actos and bladder cancer. Among the various reports damning Actos for its association with the onset of bladder cancer is a 10-year study (ongoing) undertaken by Kaiser Permanente, which found patients taking Actos for one year were 40 percent more likely to develop Actos bladder cancer compared with those who had never taken Actos. The Kaiser agency also noted the risk for bladder cancer increased with duration and dosage.
The plaintiff in the Actos lawsuit noted above had taken Actos for about five years.
Plaintiff Claims Takeda Risked Patients’ Health With Actos
Indiana resident Gerald Johnson, represented by his Actos lawyer, filed one of the many new Actos lawsuits on June 21, 2012, in the Circuit Court of Cook County, Illinois. Johnson seeks to hold manufacturer Takeda Pharmaceuticals liable for his injuries, calling the diabetes drug Actos “unreasonably dangerous.”
Johnson notes in his complaint that in the last year, Actos had global sales of $4.8 billion, which accounted for approximately 27 percent of Takeda’s revenue. In addition, back in 2008, while allegedly having knowledge of the association between long-term Actos use and bladder cancer, Takeda made Actos the tenth bestselling medication in the U.S.
A Letter from David Eisbrouch, Esq.
It should come as no surprise to an Actos lawyer that another TZD drug is back
in the spotlight after exposing patients to dangerous side effects. But this
time, the risk is less concerned with heart failure and more focused on a
certain type of cancer. Shortly after the FDA released a June 15 warning
regarding Actos bladder cancer, we began receiving calls to our Actos lawsuit phone number.
Callers who have taken the type-2 diabetes drug Actos, particularly those who have taken it in high doses for more than a year, express increasing concern that they have been exposed to a risk of which they were not previously aware. Although this particular Actos side effect has been the subject of ongoing medical investigation for some time, other recent events both here and abroad have further sparked the attention of consumers and patients worldwide. As a result, many are seeking the advice of a seasoned Actos lawyer.
On June 9th, the French Medicines Agency issued an Actos recall after data taken from their national insurance plan revealed a larger incidence of bladder cancer among patients who took Actos as compared with other TZD medications. That action came just days ahead of the FDA’s warning about Actos bladder cancer . The French Actos recall prompted a similar caution by the German Federal Institute for Drugs and Medical Devices who has suspended sales of the drug there. Last month, the first US Actos lawsuit was filed.
The Actos lawyers at Balkin & Eisbrouch are taking the lead in Actos litigation. After successfully resolving litigation against the makers of Rezulin and Avandia, Balkin & Eisbrouch provide a unique level of experience and understanding of TZD medications. Actos is the latest in the trilogy of type 2 diabetic medications in this class to jeopardize the health of patients trying to safely manage their diabetes.
Call the Actos lawsuit phone number to learn more about the developing litigation against drug manufacturer Takeda. Share your experience with an Actos lawyer and let us help you determine whether you may have a viable Actos lawsuit. We are available 24 hours a day, 7 days a week.
Callers who have taken the type-2 diabetes drug Actos, particularly those who have taken it in high doses for more than a year, express increasing concern that they have been exposed to a risk of which they were not previously aware. Although this particular Actos side effect has been the subject of ongoing medical investigation for some time, other recent events both here and abroad have further sparked the attention of consumers and patients worldwide. As a result, many are seeking the advice of a seasoned Actos lawyer.
On June 9th, the French Medicines Agency issued an Actos recall after data taken from their national insurance plan revealed a larger incidence of bladder cancer among patients who took Actos as compared with other TZD medications. That action came just days ahead of the FDA’s warning about Actos bladder cancer . The French Actos recall prompted a similar caution by the German Federal Institute for Drugs and Medical Devices who has suspended sales of the drug there. Last month, the first US Actos lawsuit was filed.
The Actos lawyers at Balkin & Eisbrouch are taking the lead in Actos litigation. After successfully resolving litigation against the makers of Rezulin and Avandia, Balkin & Eisbrouch provide a unique level of experience and understanding of TZD medications. Actos is the latest in the trilogy of type 2 diabetic medications in this class to jeopardize the health of patients trying to safely manage their diabetes.
Call the Actos lawsuit phone number to learn more about the developing litigation against drug manufacturer Takeda. Share your experience with an Actos lawyer and let us help you determine whether you may have a viable Actos lawsuit. We are available 24 hours a day, 7 days a week.
Actos recall in France
In 2011, amidst rising concerns about the health implications of the drug, an
Actos recall was
issued in France. However, at this time, Takeda has refused to issue an Actos
recall in the United States.
Subscribe to:
Posts (Atom)